Zevra Therapeutics is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system and rare disease indications that allow it to target areas with unmet needs. Co.'s prodrug product candidate pipeline is focused on the idiopathic hypersomnia (IH) and other CNS/rare diseases. Co.'s approved product, AZSTARYS®, a once-daily treatment for attention deficit hyperactivity disorder in patients, age six years and older, contains its prodrug, serdexmethylphenidate (SDX). Co.'s primary clinical development product candidate, KP1077, is based on SDX, its prodrug of d-methlyphenidate and is in development for the treatment of IH and narcolepsy. The ZVRA average annual return since 2015 is shown above.
The Average Annual Return on the ZVRA average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ZVRA average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ZVRA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ZVRA Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
